SARS-CoV-2 vaccine candidate shows promise against variants

By The Science Advisory Board staff writers

May 10, 2021 -- A pancoronavirus vaccine candidate created by the Infectious Disease Research Institute (IDRI), the Duke Human Vaccine Institute, and 3M shows potential to protect against variants of SARS-CoV-2, according to a study published May 10 in Nature.

The vaccine candidate combines a Duke-developed nanoparticle with IDRI's formulation of 3M's 3M-052 compound. The study shows that it boosts production of neutralizing antibodies against several coronavirus strains.

The drug not only could protect against coronaviruses but also reduce the need for booster shots, according to Dr. Corey Casper, CEO of IDRI.

If you like this content, please share it with a colleague!

Related Reading

StrideBio partners with Duke on novel gene therapies
StrideBio has signed a collaboration with Duke University that will support the development of next-generation gene therapies against a broad range of...

Amyris, IDRI post positive preclinical results for COVID-19 vaccine
Amyris, in partnership with the Infectious Disease Research Institute (IDRI), has released preliminary data from a preclinical study of its RNA COVID-19...

3M launches new chromatography solution for biomanufacturing
3M Health Care has launched its 3M Polisher ST product, a single-use anion exchange chromatography solution designed to replace reusable polishing columns...

Amyris, IDRI to partner on RNA vaccines
Amyris and the Infectious Disease Research Institute (IDRI) have announced that they will collaborate on the development of a new RNA vaccine platform,...

Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...